Medical treatment overview

Traditional and novel psycho-pharmacological and complementary and alternative medications

Evdokia Anagnostou, Robin L Hansen

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: Up to 35% of children and youth with autism spectrum disorder (ASD) receive at least one psychotropic medication. 50-70% of this population also receives biologically based complementary and alternative medicine (CAM). The data evaluating such practices are being reviewed. RECENT FINDINGS: There are accumulating data to suggest that atypical antipsychotics and stimulants may be useful for the treatment of irritability and hyperactivity in children and youth with ASD. The data for the use of selective serotonin reuptake inhibitors are less promising. New avenues of pharmacologic research targeting molecular targets identified by genomics, animal models and neuropathology are being evaluated. Areas of interest include glutamate/gamma-aminobutyric acid systems, neuropeptides such as oxytocin, and immune dysfunction, among others. In the case of biologically based CAM, a few compounds have been shown to be well tolerated, although efficacy is still being evaluated, such as melatonin, certain vitamins, and omega 3 fatty acids. Others have safety concerns without demonstrated efficacy, such as chelation therapies. SUMMARY: Accumulating data suggest a series of existing medications may be useful in ASD and large randomized clinical trials are necessary to evaluate safety and efficacy of both pharmaceuticals and alternative treatments.

Original languageEnglish (US)
Pages (from-to)621-627
Number of pages7
JournalCurrent Opinion in Pediatrics
Volume23
Issue number6
DOIs
StatePublished - Dec 2011

Fingerprint

Complementary Therapies
Pharmacology
Chelation Therapy
Safety
Omega-3 Fatty Acids
Serotonin Uptake Inhibitors
Oxytocin
Melatonin
Therapeutics
Genomics
Neuropeptides
Vitamins
gamma-Aminobutyric Acid
Antipsychotic Agents
Glutamic Acid
Randomized Controlled Trials
Animal Models
Research
Pharmaceutical Preparations
Population

Keywords

  • autism
  • complementary and alternative medicine
  • medication
  • pharmacology

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Medical treatment overview : Traditional and novel psycho-pharmacological and complementary and alternative medications. / Anagnostou, Evdokia; Hansen, Robin L.

In: Current Opinion in Pediatrics, Vol. 23, No. 6, 12.2011, p. 621-627.

Research output: Contribution to journalArticle

@article{dfec38f4a3e042e99cec8d175a5813ab,
title = "Medical treatment overview: Traditional and novel psycho-pharmacological and complementary and alternative medications",
abstract = "PURPOSE OF REVIEW: Up to 35{\%} of children and youth with autism spectrum disorder (ASD) receive at least one psychotropic medication. 50-70{\%} of this population also receives biologically based complementary and alternative medicine (CAM). The data evaluating such practices are being reviewed. RECENT FINDINGS: There are accumulating data to suggest that atypical antipsychotics and stimulants may be useful for the treatment of irritability and hyperactivity in children and youth with ASD. The data for the use of selective serotonin reuptake inhibitors are less promising. New avenues of pharmacologic research targeting molecular targets identified by genomics, animal models and neuropathology are being evaluated. Areas of interest include glutamate/gamma-aminobutyric acid systems, neuropeptides such as oxytocin, and immune dysfunction, among others. In the case of biologically based CAM, a few compounds have been shown to be well tolerated, although efficacy is still being evaluated, such as melatonin, certain vitamins, and omega 3 fatty acids. Others have safety concerns without demonstrated efficacy, such as chelation therapies. SUMMARY: Accumulating data suggest a series of existing medications may be useful in ASD and large randomized clinical trials are necessary to evaluate safety and efficacy of both pharmaceuticals and alternative treatments.",
keywords = "autism, complementary and alternative medicine, medication, pharmacology",
author = "Evdokia Anagnostou and Hansen, {Robin L}",
year = "2011",
month = "12",
doi = "10.1097/MOP.0b013e32834cba3e",
language = "English (US)",
volume = "23",
pages = "621--627",
journal = "Current Opinion in Pediatrics",
issn = "1040-8703",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Medical treatment overview

T2 - Traditional and novel psycho-pharmacological and complementary and alternative medications

AU - Anagnostou, Evdokia

AU - Hansen, Robin L

PY - 2011/12

Y1 - 2011/12

N2 - PURPOSE OF REVIEW: Up to 35% of children and youth with autism spectrum disorder (ASD) receive at least one psychotropic medication. 50-70% of this population also receives biologically based complementary and alternative medicine (CAM). The data evaluating such practices are being reviewed. RECENT FINDINGS: There are accumulating data to suggest that atypical antipsychotics and stimulants may be useful for the treatment of irritability and hyperactivity in children and youth with ASD. The data for the use of selective serotonin reuptake inhibitors are less promising. New avenues of pharmacologic research targeting molecular targets identified by genomics, animal models and neuropathology are being evaluated. Areas of interest include glutamate/gamma-aminobutyric acid systems, neuropeptides such as oxytocin, and immune dysfunction, among others. In the case of biologically based CAM, a few compounds have been shown to be well tolerated, although efficacy is still being evaluated, such as melatonin, certain vitamins, and omega 3 fatty acids. Others have safety concerns without demonstrated efficacy, such as chelation therapies. SUMMARY: Accumulating data suggest a series of existing medications may be useful in ASD and large randomized clinical trials are necessary to evaluate safety and efficacy of both pharmaceuticals and alternative treatments.

AB - PURPOSE OF REVIEW: Up to 35% of children and youth with autism spectrum disorder (ASD) receive at least one psychotropic medication. 50-70% of this population also receives biologically based complementary and alternative medicine (CAM). The data evaluating such practices are being reviewed. RECENT FINDINGS: There are accumulating data to suggest that atypical antipsychotics and stimulants may be useful for the treatment of irritability and hyperactivity in children and youth with ASD. The data for the use of selective serotonin reuptake inhibitors are less promising. New avenues of pharmacologic research targeting molecular targets identified by genomics, animal models and neuropathology are being evaluated. Areas of interest include glutamate/gamma-aminobutyric acid systems, neuropeptides such as oxytocin, and immune dysfunction, among others. In the case of biologically based CAM, a few compounds have been shown to be well tolerated, although efficacy is still being evaluated, such as melatonin, certain vitamins, and omega 3 fatty acids. Others have safety concerns without demonstrated efficacy, such as chelation therapies. SUMMARY: Accumulating data suggest a series of existing medications may be useful in ASD and large randomized clinical trials are necessary to evaluate safety and efficacy of both pharmaceuticals and alternative treatments.

KW - autism

KW - complementary and alternative medicine

KW - medication

KW - pharmacology

UR - http://www.scopus.com/inward/record.url?scp=80955168686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80955168686&partnerID=8YFLogxK

U2 - 10.1097/MOP.0b013e32834cba3e

DO - 10.1097/MOP.0b013e32834cba3e

M3 - Article

VL - 23

SP - 621

EP - 627

JO - Current Opinion in Pediatrics

JF - Current Opinion in Pediatrics

SN - 1040-8703

IS - 6

ER -